Form 4: PAVmed COO Granted 150,000 Restricted Shares

PAVmed Inc.'s Chief Operating Officer, Shaun O'Neil, was granted 150,000 restricted common shares as part of the company's long-term incentive plan.

Summary

• Shaun O'Neil, Chief Operating Officer of PAVmed Inc., was granted 150,000 shares of common stock.
• The transaction date for this grant was September 30, 2025.
• The shares were granted at a price of $0, indicating they are restricted stock.
• The grant was made under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan.
• These restricted shares are subject to a single vesting date of May 20, 2028.
• The shares are subject to forfeiture if the requisite service period is not completed.
• Following this transaction, Shaun O'Neil beneficially owns 167,933 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive is generally a positive signal, indicating management alignment with long-term shareholder interests and executive retention. It does not, however, directly reflect immediate financial performance.

Positives

• The grant of restricted stock to the Chief Operating Officer aligns management's long-term interests with those of shareholders.
• It serves as a long-term incentive for the executive to remain with the company and contribute to its success.

Negatives

• The shares are restricted and subject to forfeiture, meaning the executive does not have immediate full ownership.
• There is no immediate cash value realized by the executive from this grant.

Risks

• The restricted stock is subject to forfeiture if the requisite service period is not completed by the vesting date of May 20, 2028.

Future Outlook

The restricted stock grant to the Chief Operating Officer implies a continued long-term commitment from a key executive, aligning their incentives with the company's future performance and shareholder value creation.

Industry Context

Equity grants, particularly restricted stock, are a common component of executive compensation packages across various industries, including the medical technology sector. They are designed to incentivize long-term performance and retention of key personnel.

Comparison to Industry Standards

• The use of restricted stock as a long-term incentive for executives is a standard practice within the medical technology and broader corporate landscape.
• The vesting schedule, while specific to this grant, is typical for encouraging executive retention over several years.

Corporate Governance

Related Party Transactions

• Grant of 150,000 restricted common shares to Shaun O'Neil, the Chief Operating Officer, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation over the long term.
• Employees: Signals continued commitment from a key executive, potentially fostering stability.

Next Steps

• The restricted shares will vest on May 20, 2028, provided the requisite service period is completed.

Key Dates

Recommendation

The grant of restricted stock to a key executive like the Chief Operating Officer signals continued commitment and aligns management's long-term interests with those of shareholders. While not a direct indicator of immediate financial performance, it's a positive governance signal that supports a 'hold' recommendation, suggesting stability and confidence in the company's future without providing a strong catalyst for immediate buying or selling.

Keywords

PAVmed, PAVM, Shaun O'Neil, restricted stock, equity grant, COO, insider transaction, Form 4, long-term incentive, executive compensation